Abiomed, Inc.
- Jurisdiction
United States - LEI
5493001EZN4ZTB4Z5887 - ISIN
US0036541003 (ABMD )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. Read full profile
Fundamentals
- Net revenue
€916.15M - Gross margin
81.3% - EBIT
€216.32M - EBIT margin
23.6% - Net income
€227.54M - Net margin
24.8%
Statement period: - (published )
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Earnings Calls
Latest earnings call: November 1, 2022 (Q2 2023)